Analyst Research

Report Title Price
Provider: New Constructs, LLC
Provider: S&P Capital IQ Quantitative Report
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cleveland BioLabs Inc completion of Phase 1 Study of CBL0102

Wednesday, 16 Apr 2014 08:00am EDT 

Cleveland BioLabs Inc:Achievement of all objectives in Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule.Study was performed in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies.Patients had tumors involving liver.L0102 is first of group of compounds identified by CBLI scientists that act by blocking activity of chromatin remodeling complex. 

Company Quote

0.5 +13.48%
29 Jan 2015